637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome
Jacqueline S. Garcia, Andrew H. Wei, Meagan A. Jacoby, et al.In MDS with a higher risk, Venetoclax plus Azacitidine leads to a rapid and sustained response and high remission rates. Meaningful clinical and molecular responses were observed in all major mutation profiles. Updated data will be presented in the oral session.
Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, et al.
See abstract for more info.
Pierre Peterlin, Pascal Turlure, Patrice Chevallier, et al.
The study authors show that CPX-351 is effective for MDS/CMML with higher risk. This is particularly true for achieving blast clearance and as a bridge to allo SCT.
Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, et al.
Sabatolimab + HMA demonstrated a sustained clinical response in patients with vHR / HR-MDS and ND-AM. According to the study authors, the combination is safe and well-tolerated.
Sangeetha Venugopal, Hagop Kantarjian, Abhishek Maiti, et al.
The combination Venetoclax + ASTX727 (cedazuridine/decitabine) appears to be safe according to the study authors. It demonstrates preliminary efficacy in patients with MDS or CMML at increased risk and excess blasts.
David A. Sallman, Rami S. Komrokji, Amy E. DeZern, et al.
Treatment of eprenetapopt (APR-246) and azacitidine (AZA) in mTP53 MDS/AML was well tolerated and high response rates were achieved.